Skip to main content

Europe's Long Energy Journey

Image result for solar panels on roof

The headline of this post is the title of a new book by David Buchan and Malcolm Keay. The subtitle is "Toward an Energy Union?".

The general theme of the book is that the EU's reforms on energy related issues have so far been inadequate. They have been too optimistic about the consequences of market liberalization and have underestimated the costs that would be associated with cuts in emissions.

The authors spend a fair amount of time on the issue of feed-in tariffs (FIT). These are the deals that member states are willing to offer alternative electricity generators, including for example homeowners who might simply have solar panels on their roof. The payments are determined by technology, and in essence by politics, so kilowatts are not treated as fungible. Though of course once it gets into the grid, a kilowatt is a kilowatt and is indifferent to where it came from.

Feed-in tariffs have proven very popular. Every nation state that creates them finds that it has created a vocal constituency for preserving them:  those homeowners with solar cells on the roof come to rely on that as a source of income and are perfectly willing to agitate for its preservation or for higher rates. This makes the EU a bit of a patchwork.

Lauren McKee has reviewed the book quite favorably here.

McKee concludes her review with reflections on Brexit. Unless it changes course, the United Kingdom will "lose EU funding for energy infrastructure and it may be more difficult for multinationals to work in the North Sea area."

The long journey continues. And as four lads from Liverpool might once have sung, it is a long and winding road.

Comments

  1. There is a chance you qualify for a new solar energy rebate program.
    Click here and find out if you're qualified now!

    ReplyDelete

Post a Comment

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…